NCT06000033尚未招募2 期
Combination of Disitamab Vedotin and Anlotinib in the Treatment of HR-Negative, HER2-Low-Expressing Metastatic Breast Cancer: A Single-Arm, Multicenter, Phase II Clinical Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 35
- 主要终点
- Objective response rate (ORR)
研究概览
简要总结
Disitamab Vedotin (RC48) contains the novel humanized anti-HER2 antibody conjugated to monomethyl auristatin E (MMAE) via a cleavable linker , which is the first ADC drug that was independently developed by Rongchang Biology .The aim of this study is to evaluate the efficacy and safety of RC48 in Combination with Anlotinib for the treatment of metastatic breast cancer with HR negativity and HER2 low expression.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •At the time of signing the informed consent form, the age is ≥ 18 years old, regardless of gender;
- •Patients with pathohistologically proven, locally advanced or metastatic breast cancer have progressed through second-line standard treatment;
- •The immunohistochemical (IHC) test results of archived tissue (within 6 months) or fresh biopsy lesions were negative for ER and PR, while patients with low HER-2 expression were HR -, HER2IHC1+, or HER2IHC2+and ISH negative;
- •ECOGPS: 0-1 points;
- •Expected survival time>12 weeks;
- •Adequate organ function: bone marrow function: hemoglobin ≥ 9g/dL; Absolute neutrophil count ≥ 1.5 × 109/L; White blood cell count ≥ 3.0 × 109/L; Platelets ≥ 100 × 109/L; Liver function: serum total bilirubin ≤ 1.5 times the upper limit of normal value (ULN); Aspartic acid Transaminase (AST) and alanine Transaminase (ALT) ≤ 3.0 × ULN (or ≤ 5.0 in the presence of liver metastasis) × ULN) Renal function: blood creatinine ≤ 1.5 × The creatinine clearance rate (CrCl) calculated by ULN or Cockcroft Fault formula method is ≥ 60mL/min; Cardiac function: New York Heart Association (NYHA) grading<3; Left ventricular Ejection fraction ≥ 50%;
- •At least one measurable lesion defined in RECIST version 1.1;
- •Women of childbearing age must have taken reliable contraceptive measures or conducted a Pregnancy test (serum or urine) within 7 days before enrollment, and the result is negative, and are willing to use appropriate methods of contraception during the test and 8 weeks after the last administration of the test drug. For males, it is necessary to agree to use appropriate methods of contraception or undergo surgical sterilization during the trial period and 8 weeks after the last administration of the investigational drug;
- •The subjects voluntarily joined this study and signed an informed consent form, with good compliance and cooperation in follow-up.
排除标准
- •The second-line treatment within 3 months is paclitaxel drug therapy;
- •Received antitumor therapy or radiation therapy for any malignancy within the previous five years, excluding cured cervical carcinoma in situ, skin basal cell carcinoma, or squamous cell carcinoma;
- •had a major non-breast cancer related surgery in the 4 weeks prior to enrollment, or had not fully recovered from such surgery;
- •Previously received ADC drugs, anti-angiogenesis drugs, anti-HER2 and other treatments;
- •Serious cardiovascular and cerebrovascular disease or discomfort, including but not limited to the following diseases: - History of confirmed heart failure or systolic dysfunction (LVEF<50%) - high-risk uncontrolled arrhythmias - angina, acute myocardial infarction - clinically significant valvular heart disease - poorly controlled hypertension (systolic blood pressure >180mmHg and/or diastolic blood pressure >100mmHg)
- •known allergic history of the drug components of this protocol;
- •A history of immunodeficiency, including HIV testing positive, or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation;
- •symptomatic brain metastases or brain metastases (excluding prophylactic cranial irradiation) within 4 weeks prior to initiation of treatment; 9) Pregnant and lactating women, fertile women who tested positive for baseline pregnancy tests, or patients of childbearing age who were unwilling to take effective contraception throughout the trial period;
- •Have a serious concomitant condition or other comorbid condition that interferes with planned treatment, or any other condition in which the investigator deems the patient unsuitable for participation in the study.
研究组 & 干预措施
RC48+Anlotinib
Experimental
Disitamab Vedotin : 2 mg/kg，ivgtt，d1-14/28day/cycle Anlotinib: 12mg once daily (taken before meals) orally, continuously for 2 weeks followed by a 1-week break. Each cycle consists of 21 days.
干预措施: Disitamab Vedotin+Anlotinib (Drug)
结局指标
主要结局
Objective response rate (ORR)
时间窗: 1year
The percentage of cases that have achieved complete or partial remission after drug treatment compared to the total evaluable cases.
次要结局
- Overall Survival (OS)(2years)
- Progression-Free Survival (PFS)(2years)
- Duration of Response (DOR)(1year)
- Disease Control Rate (DCR)(1year)
- AEs(2years)
研究者
相似试验
招募中
2 期
Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Breast CancerLocally Advanced Breast CancerChemotherapy EffectNCT05749016Cancer Institute and Hospital, Chinese Academy of Medical Sciences30
招募中
2 期
RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal CancerColorectal CancerNCT05578287Sun Yat-sen University29
招募中
不适用
RC48-ADC in HER2-low Advanced Breast CancerAdvanced Breast CancerNCT05831878RenJi Hospital36
招募中
2 期
RC48 in Combination With AK104 and Bevacizumab in OCCCOvary CancerNCT06540729Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University39
尚未招募
2 期
Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 AlterationsNon Small Cell Lung CancerERBB2 Mutation-Related TumorsRC48Disitamab VedotinNCT05847764Sun Yat-sen University95